Recent Updates
Recently added Catalysts
HAE Positive Sentiment

Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond...

Key Takeaway: Haemonetics Corporation announced that CEO Chris Simon will participate in a fireside chat at the Raymond James 47th Annual Institutional Investors Conference on March 2, 2026. The event will be accessible via a live webcast, with a replay available for 90 days afterward. This engagement aims to enhance investor relations and showcase the company's medical technology innovations.
Price reaction · baseline $60.67 (2026-02-19 close) · hit after-hours · 2 other HAE headline(s) in the window, move may be shared
day 0 close · peak
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Chris Simon will engage with investors, enhancing transparency.
  • The event provides a platform for Haemonetics to showcase its innovations.
  • Live webcast allows broader access to the company's insights.

Full Press Release Details

BOSTON , Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE ) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET.
The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.summitcast.com/view/VSr8zRPFYu9jT7Rm69ptdC/DrZt2UmuNYtnB5faJBzE4N .
A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our innovative solutions addressing critical medical needs include a suite of hospital technologies designed to advance standards of care and help enhance outcomes for patients; end-to-end plasma collection technologies to optimize operations for plasma centers; and products to enable blood centers to collect in-demand blood components. To learn more about Haemonetics, visit www.haemonetics.com .
Investor Contacts:
Olga Guyette, Vice President-Investor Relations & Treasury
David Trenk, Manager-Investor Relations
(781) 356-9763
(203) 733-4987
[email protected]
[email protected]
Media Contact:
Josh Gitelson, Sr. Director-Global Communications
(781) 356-9776
[email protected]

Frequently Asked Questions

When will the Haemonetics conference take place?

The Haemonetics conference is scheduled for March 2, 2026.

How can I access the Haemonetics fireside chat?

The fireside chat can be accessed via a live webcast on Haemonetics' Investor Relations website.

Who will represent Haemonetics at the conference?

Chris Simon, the President and CEO of Haemonetics, will represent the company.

Will the conference be available for replay?

Yes, a replay of the webcast will be available for 90 days after the event.

Last updated: Feb 20, 2026